Glox Therapeutics develops precision, engineered protein bacteriocins to target drug-resistant pathogenic bacteria. The company is working on the development of precision antibiotics to combat antimicrobial resistance.
investor of
Metrics
marketPRIVATE
msh_idCOM:GLOXTHERAPEUTICS
localeus
websitehttps://gloxtherapeutics.com
source_ref15582419-9740-493f-b20a-aa028ce26712
products_or_servicesDevelopment of precision antibiotics and engineered protein bacteriocins
United States